Sustar Ursa, Groselj Urh, Khan Sabeen Abid, Shafi Saeed, Khan Iqbal, Kovac Jernej, Bizjan Barbara Jenko, Battelino Tadej, Sadiq Fouzia
Department of Endocrinology, Diabetes and Metabolism, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Front Genet. 2022 Aug 16;13:983283. doi: 10.3389/fgene.2022.983283. eCollection 2022.
Due to nonspecific symptoms, rare dyslipidaemias are frequently misdiagnosed, overlooked, and undertreated, leading to increased risk for severe cardiovascular disease, pancreatitis and/or multiple organ failures before diagnosis. Better guidelines for the recognition and early diagnosis of rare dyslipidaemias are urgently required. Genomic DNA was isolated from blood samples of a Pakistani paediatric patient with hypertriglyceridemia, and from his parents and siblings. Next-generation sequencing (NGS) was performed, and an expanded dyslipidaemia panel was employed for genetic analysis. The NGS revealed the presence of a homozygous missense pathogenic variant c.230G>A (NM_178172.6) in exon 3 of the (glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1) gene resulting in amino acid change p.Cys77Tyr (NP_835466.2). The patient was 5.5 years old at the time of genetic diagnosis. The maximal total cholesterol and triglyceride levels were measured at the age of 10 months (850.7 mg/dl, 22.0 mmol/L and 5,137 mg/dl, 58.0 mmol/L, respectively). The patient had cholesterol deposits at the hard palate, eruptive xanthomas, lethargy, poor appetite, and mild splenomegaly. Both parents and sister were heterozygous for the familial variant in the gene. Moreover, in the systematic review, we present 62 patients with pathogenic variants in the gene and clinical findings, associated with hyperlipoproteinemia. In a child with severe hypertriglyceridemia, we identified a pathogenic variant in the gene causing hyperlipoproteinemia (type 1D). In cases of severe elevations of plasma cholesterol and/or triglycerides genetic testing for rare dyslipidaemias should be performed as soon as possible for optimal therapy and patient management.
由于症状不具特异性,罕见血脂异常常被误诊、漏诊和治疗不足,导致在诊断前发生严重心血管疾病、胰腺炎和/或多器官功能衰竭的风险增加。因此,迫切需要更好的罕见血脂异常识别和早期诊断指南。从一名患有高甘油三酯血症的巴基斯坦儿科患者及其父母和兄弟姐妹的血样中分离出基因组DNA。进行了下一代测序(NGS),并使用扩展的血脂异常检测板进行基因分析。NGS结果显示,(糖基磷脂酰肌醇锚定高密度脂蛋白结合蛋白1)基因第3外显子存在纯合错义致病变体c.230G>A(NM_178172.6),导致氨基酸改变p.Cys77Tyr(NP_835466.2)。该患者在基因诊断时为5.5岁。在10个月大时测量的总胆固醇和甘油三酯水平最高(分别为850.7mg/dl、22.0mmol/L和5137mg/dl、58.0mmol/L)。患者硬腭有胆固醇沉积、发疹性黄瘤、嗜睡、食欲不振和轻度脾肿大。父母和姐姐在该基因中的家族变体均为杂合子。此外,在系统评价中,我们报告了62例该基因致病变体患者及其与高脂蛋白血症相关的临床发现。在一名患有严重高甘油三酯血症的儿童中,我们在该基因中鉴定出一个导致高脂蛋白血症(1D型)的致病变体。对于血浆胆固醇和/或甘油三酯严重升高的病例,应尽快进行罕见血脂异常的基因检测,以实现最佳治疗和患者管理。